=> d his full

(FILE 'HOME' ENTERED AT 21:54:17 ON 02 JUN 2006)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 21:54:43 ON 02 JUN 2006

SEA SECRET?(S)(LYSOS? OR GRANUL?)

84	FILE ADISCTI
35	FILE ADISINSIGHT
28	FILE ADISNEWS
664	FILE AGRICOLA
11	FILE ANABSTR
1	FILE ANTE
8	FILE AQUALINE
1121	FILE AQUASCI
444	FILE BIOENG
16593	FILE BIOSIS
627	FILE BIOTECHABS
627	FILE BIOTECHDS
6865	FILE BIOTECHNO
3367	FILE CABA
13868	FILE CAPLUS
46	FILE CEABA-VTB
6	FILE CIN
234	FILE CONFSCI
10	FILE CROPU
193	FILE DDFB
600	FILE DDFU
2057	FILE DGENE
920	FILE DISSABS
193	FILE DRUGB
1247	FILE DRUGU
120	FILE EMBAL
13368	FILE EMBASE
7230	FILE ESBIOBASE
10	FILE FROSTI
30	FILE FSTA
551	FILE GENBANK
15	FILE HEALSAFE
370	FILE IFIPAT
9	FILE IMSDRUGNEWS
8	FILE IMSRESEARCH
1738	FILE JICST-EPLUS
50	FILE KOSMET
5161	FILE LIFESCI
14017	FILE MEDLINE
93	FILE NTIS
1	FILE NUTRACEUT
168	FILE OCEAN
6612	FILE PASCAL
5	FILE PHAR
5	FILE PHARMAML
36	FILE PHIN
289	FILE PROMT
13	FILE PROUSDDR
8	FILE RDISCLOSURE
10143	FILE SCISEARCH
4249	FILE TOXCENTER
7252	FILE USPATFULL
701	FILE USPAT2
3	FILE VETB
112	FILE VETU
12	FILE WATER
568	FILE WPIDS
5	FILE WPIFV

568 FILE WPINDEX
33 FILE IPA
12 FILE NAPRALERT
207 FILE NLDB

L1 QUE SECRET?(S)(LYSOS? OR GRANUL?)

D RANK

FILE 'BIOSIS, MEDLINE, CAPLUS, EMBASE, SCISEARCH, USPATFULL, ESBIOBASE, BIOTECHNO, PASCAL, LIFESCI, TOXCENTER, CABA' ENTERED AT 21:57:35 ON 02 JUN 2006

L2 108725 SEA SECRET?(S)(LYSOS? OR GRANUL?)
L3 9324 SEA L2(S) LOCAL?
L4 887 SEA L3(S)(PROTEAS? OR TRYPTAS? OR CHYMAS? OR CATHEPS? OR CARBOXYPEPTIDAS? OR PROTEINAS? OR HEXOSAMIDA?)
L5 716 SEA L4(S) CELL?
L6 146 SEA L5(S) MAST?
L7 76 DUP REM L6 (70 DUPLICATES REMOVED)
D TI L7 1-76
D IBIB ABS L7 6 8 11 24 29 30 33 36 37 39 54 58 64 74 76
L8 27 SEA L7 AND FUS?
D TI L8 1-28
L9 181 SEA L5 AND MAST?
L10 60 SEA L9 AND FUS?
L11 59 DUP REM L10 (1 DUPLICATE REMOVED)
D TI L11 1-59
D L11 IBIB ABS 21 47 53 58

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1652dmr

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 4	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS 5	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS 6	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS 7	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 8	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 9	MAR 22	EMBASE is now updated on a daily basis
NEWS 10	APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 11	APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS 12	APR 04	STN AnaVist $500 visualization usage credit offered
NEWS 13	APR 12	LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS 14	APR 12	Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS 15	APR 12	Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected
NEWS 16	MAY 10	CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 17	MAY 11	KOREAPAT updates resume
NEWS 18	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS 19	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2
NEWS 20	MAY 30	The F-Term thesaurus is now available in CA/CAplus
NEWS 21	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS EXPRESS		FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT http://download.cas.org/express/v8.0-Discover/
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS LOGIN		Welcome Banner and News Items
NEWS IPC8		For general information regarding STN implementation of IPC 8
NEWS X25		X.25 communication option no longer available after June 2006

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

```
FILE 'HOME' ENTERED AT 21:54:17 ON 02 JUN 2006

=> index bioscience medicine
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
       AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
       CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
       DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 21:54:43 ON 02 JUN 2006

71 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s secret?(s)(lysos? or granul?)
         84   FILE ADISCTI
         35   FILE ADISINSIGHT
         28   FILE ADISNEWS
        664   FILE AGRICOLA
         11   FILE ANABSTR
          1   FILE ANTE
          8   FILE AQUALINE
       1121   FILE AQUASCI
        444   FILE BIOENG
      16593   FILE BIOSIS
        627   FILE BIOTECHABS
        627   FILE BIOTECHDS
       6865   FILE BIOTECHNO
       3367   FILE CABA
      13868   FILE CAPLUS
         46   FILE CEABA-VTB
          6   FILE CIN
        234   FILE CONFSCI
         10   FILE CROPU
        193   FILE DDFB
        600   FILE DDFU
  22 FILES SEARCHED...
       2057   FILE DGENE
        920   FILE DISSABS
        193   FILE DRUGB
       1247   FILE DRUGU
        120   FILE EMBAL
      13368   FILE EMBASE
       7230   FILE ESBIOBASE
         10   FILE FROSTI
         30   FILE FSTA
        551   FILE GENBANK
         15   FILE HEALSAFE
        370   FILE IFIPAT
          9   FILE IMSDRUGNEWS
          8   FILE IMSRESEARCH
       1738   FILE JICST-EPLUS
         50   FILE KOSMET
       5161   FILE LIFESCI
      14017   FILE MEDLINE
  44 FILES SEARCHED...
         93   FILE NTIS
          1   FILE NUTRACEUT
        168   FILE OCEAN
       6612   FILE PASCAL
```

```
          5   FILE PHAR
          5   FILE PHARMAML
         36   FILE PHIN
        289   FILE PROMT
         13   FILE PROUSDDR
          8   FILE RDISCLOSURE
      10143   FILE SCISEARCH
       4249   FILE TOXCENTER
       7252   FILE USPATFULL
        701   FILE USPAT2
          3   FILE VETB
        112   FILE VETU
         12   FILE WATER
  65 FILES SEARCHED...
        568   FILE WPIDS
          5   FILE WPIFV
        568   FILE WPINDEX
         33   FILE IPA
         12   FILE NAPRALERT
        207   FILE NLDB

  62 FILES HAVE ONE OR MORE ANSWERS,    71 FILES SEARCHED IN STNINDEX

L1    QUE SECRET?(S)(LYSOS? OR GRANUL?)

=> d rank
F1        16593   BIOSIS
F2        14017   MEDLINE
F3        13868   CAPLUS
F4        13368   EMBASE
F5        10143   SCISEARCH
F6         7252   USPATFULL
F7         7230   ESBIOBASE
F8         6865   BIOTECHNO
F9         6612   PASCAL
F10        5161   LIFESCI
F11        4249   TOXCENTER
F12        3367   CABA
F13        2057   DGENE
F14        1738   JICST-EPLUS
F15        1247   DRUGU
F16        1121   AQUASCI
F17         920   DISSABS
F18         701   USPAT2
F19         664   AGRICOLA
F20         627   BIOTECHABS
F21         627   BIOTECHDS
F22         600   DDFU
F23         568   WPIDS
F24         568   WPINDEX
F25         551   GENBANK
F26         444   BIOENG
F27         370   IFIPAT
F28         289   PROMT
F29         234   CONFSCI
F30         207   NLDB
F31         193   DDFB
F32         193   DRUGB
F33         168   OCEAN
F34         120   EMBAL
F35         112   VETU
F36          93   NTIS
F37          84   ADISCTI
F38          50   KOSMET
F39          46   CEABA-VTB
```

```
F40          36   PHIN
F41          35   ADISINSIGHT
F42          33   IPA
F43          30   FSTA
F44          28   ADISNEWS
F45          15   HEALSAFE
F46          13   PROUSDDR
F47          12   WATER
F48          12   NAPRALERT
F49          11   ANABSTR
F50          10   CROPU
F51          10   FROSTI
F52           9   IMSDRUGNEWS
F53           8   AQUALINE
F54           8   IMSRESEARCH
F55           8   RDISCLOSURE
F56           6   CIN
F57           5   PHAR
F58           5   PHARMAML
F59           5   WPIFV
F60           3   VETB
F61           1   ANTE
F62           1   NUTRACEUT


=> file f1-f12
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     3.05       3.26

FILE 'BIOSIS' ENTERED AT 21:57:35 ON 02 JUN 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 21:57:35 ON 02 JUN 2006

FILE 'CAPLUS' ENTERED AT 21:57:35 ON 02 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 21:57:35 ON 02 JUN 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 21:57:35 ON 02 JUN 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'USPATFULL' ENTERED AT 21:57:35 ON 02 JUN 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'ESBIOBASE' ENTERED AT 21:57:35 ON 02 JUN 2006
COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'BIOTECHNO' ENTERED AT 21:57:35 ON 02 JUN 2006
COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'PASCAL' ENTERED AT 21:57:35 ON 02 JUN 2006
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2006 INIST-CNRS. All rights reserved.

FILE 'LIFESCI' ENTERED AT 21:57:35 ON 02 JUN 2006
COPYRIGHT (C) 2006 Cambridge Scientific Abstracts (CSA)
```

```
FILE 'TOXCENTER' ENTERED AT 21:57:35 ON 02 JUN 2006
COPYRIGHT (C) 2006 ACS

FILE 'CABA' ENTERED AT 21:57:35 ON 02 JUN 2006
COPYRIGHT (C) 2006 CAB INTERNATIONAL (CABI)

=> s secret?(s)(lysos? or granul?)
L2      108725 SECRET?(S)(LYSOS? OR GRANUL?)

=> s l2(s) local?
L3        9324 L2(S) LOCAL?

=> s l3(s)(proteas? or tryptas? or chymas? or catheps? or carboxypeptidas? or
proteinas? or hexosamida?)
L4         887 L3(S)(PROTEAS? OR TRYPTAS? OR CHYMAS? OR CATHEPS? OR CARBOXYPEP
               TIDAS? OR PROTEINAS? OR HEXOSAMIDA?)

=> s l4(s)cell?
   7 FILES SEARCHED...
   9 FILES SEARCHED...
L5         716 L4(S) CELL?

=> s l5(s)mast?
L6         146 L5(S) MAST?

=> dup rem l6
PROCESSING COMPLETED FOR L6
L7           76 DUP REM L6 (70 DUPLICATES REMOVED)

=> d ti l7 1-76

L7   ANSWER 1 OF 76  USPATFULL on STN
TI     RT-PCR-based cloning of the human beta-amyloid precursor protein gene
       and the construction of its expression plasmids

L7   ANSWER 2 OF 76  USPATFULL on STN
TI     Novel inhibitors of chymase

L7   ANSWER 3 OF 76  USPATFULL on STN
TI     Cancer treatment methods using selected antibodies to aminophospholipids

L7   ANSWER 4 OF 76  USPATFULL on STN
TI     Cancer treatment methods using selected immunoconjugates for binding to
       aminophospholipids

L7   ANSWER 5 OF 76  USPATFULL on STN
TI     Composition, synthesis and therapeutic applications of polyamines

L7   ANSWER 6 OF 76  USPATFULL on STN
TI     Method to identify and analyze genes having modified expression in
       activated cells with secretory lysosomes

L7   ANSWER 7 OF 76  USPATFULL on STN
TI     Novel amine derivative having human beta-tryptase inhibitory activity
       and drugs containing the same

L7   ANSWER 8 OF 76  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   A role for cathepsin E in the processing of mast-cell carboxypeptidase A

L7    ANSWER 9 OF 76  Elsevier BIOBASE  COPYRIGHT 2006 Elsevier Science B.V. on
      STN                                                DUPLICATE
TI    Mast cell tryptase may modulate endothelial cell phenotype in healing
      myocardial infarcts

L7   ANSWER 10 OF 76  USPATFULL on STN
```

TI Lp mammalian proteins; related reagents

L7 ANSWER 11 OF 76 USPATFULL on STN
TI Methods and compositions for targeting secretory lysosomes

L7 ANSWER 12 OF 76 USPATFULL on STN
TI Purified proenzyme of dipeptidyl peptidase i (pro-dppi)

L7 ANSWER 13 OF 76 USPATFULL on STN
TI Proteins and nucleic acids encoding same

L7 ANSWER 14 OF 76 USPATFULL on STN
TI Novel polypeptides and nucleic acids encoding same

L7 ANSWER 15 OF 76 PASCAL COPYRIGHT 2006 INIST-CNRS. ALL RIGHTS RESERVED. on STN
TIEN Mast cells and hemangioma

L7 ANSWER 16 OF 76 USPATFULL on STN
TI Method of treating interleukin-6-mediated inflammatory diseases

L7 ANSWER 17 OF 76 USPATFULL on STN
TI Novel polypeptides and nucleic acids encoding same

L7 ANSWER 18 OF 76 USPATFULL on STN
TI Novel polypeptides and nucleic acids encoding same

L7 ANSWER 19 OF 76 USPATFULL on STN
TI Novel polypeptides and nucleic acids encoding same

L7 ANSWER 20 OF 76 USPATFULL on STN
TI Novel proteins and nucleic acids encoding same

L7 ANSWER 21 OF 76 USPATFULL on STN
TI Interventions to mimic the effects of calorie restriction

L7 ANSWER 22 OF 76 USPATFULL on STN
TI Novel polypeptides and nucleic acids encoding same

L7 ANSWER 23 OF 76 USPATFULL on STN
TI Novel polypeptides and nucleic acids encoding same

L7 ANSWER 24 OF 76 Elsevier BIOBASE COPYRIGHT 2006 Elsevier Science B.V. on STN DUPLICATE
TI IL-1 Induces Vesicular Secretion of IL-6 without Degranulation from Human Mast Cells

L7 ANSWER 25 OF 76 Elsevier BIOBASE COPYRIGHT 2006 Elsevier Science B.V. on STN DUPLICATE
TI Isolation of Mast Cell Secretory Lysosomes Using Flow Cytometry

L7 ANSWER 26 OF 76 USPATFULL on STN
TI Method for reducing or preventing the establishment, growth or metastasis of cancer by administering benzimidazolone peptidomimetics PAR-1 antagonist and optionally PAR-2 antagonists

L7 ANSWER 27 OF 76 USPATFULL on STN
TI Method for reducing or preventing the establishment, growth or metastasis of cancer by administering indole peptidomimetics PAR-1 antagonist and optionally PAR-2 antagonists

L7 ANSWER 28 OF 76 USPATFULL on STN
TI Method for reducing or preventing the establishment, growth or metastasis of cancer by administering PAR-1 and optionally PAR-2 antagonists

L7 ANSWER 29 OF 76 USPATFULL on STN
TI Method for reducing or preventing the establishment, growth or metastasis of cancer by administering indazole peptidomimetics PAR-1 antagonist and optionally PAR-2 antagonists

L7 ANSWER 30 OF 76 USPATFULL on STN
TI Natural product composition for decreasing IgE production and treating secondary allergic responses

L7 ANSWER 31 OF 76 USPATFULL on STN
TI Interventions to mimic the effects of calorie restriction

L7 ANSWER 32 OF 76 Elsevier BIOBASE COPYRIGHT 2006 Elsevier Science B.V. on STN DUPLICATE
TI Enteric expression of the integrin α.sub.vβ.sub.6 is essential for nematode-induced mucosal mast cell hyperplasia and expression of the granule chymase, mouse mast cell protease-1

L7 ANSWER 33 OF 76 Elsevier BIOBASE COPYRIGHT 2006 Elsevier Science B.V. on STN DUPLICATE
TI Tissue-specific expression of mast cell granule serine proteinases and their role in inflammation in the lung and gut

L7 ANSWER 34 OF 76 USPATFULL on STN
TI Phospholipase D gene

L7 ANSWER 35 OF 76 Elsevier BIOBASE COPYRIGHT 2006 Elsevier Science B.V. on STN DUPLICATE
TI Human mast cells release metalloproteinase-9 on contact with activated T cells: Juxtacrine regulation by TNF-α

L7 ANSWER 36 OF 76 Elsevier BIOBASE COPYRIGHT 2006 Elsevier Science B.V. on STN
TI Secretory granules of mast cells accumulate mature and immature MHC class II molecules

L7 ANSWER 37 OF 76 MEDLINE on STN
TI Role of chymase on vascular proliferation.

L7 ANSWER 38 OF 76 Elsevier BIOBASE COPYRIGHT 2006 Elsevier Science B.V. on STN
TI The lysosomal protease cathepsin D is efficiently sorted to and secreted from regulated secretory compartments in the rat basophilic/mast cell line RBL

L7 ANSWER 39 OF 76 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 7
TI Latexin, a carboxypeptidase A inhibitor, is expressed in rat peritoneal mast cells and is associated with granular structures distinct from secretory granules and lysosomes

L7 ANSWER 40 OF 76 Elsevier BIOBASE COPYRIGHT 2006 Elsevier Science B.V. on STN
TI Dipeptidyl peptidase I cleaves matrix-associated proteins and is expressed mainly by mast cells in normal dog airways

L7 ANSWER 41 OF 76 CAPLUS COPYRIGHT 2006 ACS on STN
TI Role of chymase on vascular proliferation

L7 ANSWER 42 OF 76 USPATFULL on STN
TI Mast cell protease that cleaves fibrinogen

L7 ANSWER 43 OF 76 Elsevier BIOBASE COPYRIGHT 2006 Elsevier Science B.V. on STN DUPLICATE
TI Contribution of mast cells to the tubulointerstitial lesions in IgA

nephritis

L7 ANSWER 44 OF 76 Elsevier BIOBASE COPYRIGHT 2006 Elsevier Science B.V. on STN DUPLICATE
TI Stem cell factor in mast cells and increased mast cell density in idiopathic and ischemic cardiomyopathy

L7 ANSWER 45 OF 76 Elsevier BIOBASE COPYRIGHT 2006 Elsevier Science B.V. on STN DUPLICATE
TI Immunocytochemical localization of chymase to cytoplasmic vesicles after rat peritoneal mast cell stimulation by compound 48/80

L7 ANSWER 46 OF 76 Elsevier BIOBASE COPYRIGHT 2006 Elsevier Science B.V. on STN DUPLICATE
TI Mast cell and mast cell granule phenotypes in normal and Nippostrongylus-infected rats. A qualitative laser confocal microscopic study

L7 ANSWER 47 OF 76 Elsevier BIOBASE COPYRIGHT 2006 Elsevier Science B.V. on STN DUPLICATE
TI Molecular and cellular biology of mast cells and basophils

L7 ANSWER 48 OF 76 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 13
TI PH dependence of bovine mast cell tryptase catalytic activity and of its inhibition by 4',6-diamidino-2-phenylindole.

L7 ANSWER 49 OF 76 PASCAL COPYRIGHT 2006 INIST-CNRS. ALL RIGHTS RESERVED. on STN
TIEN Human synovial mast cells. I. Ultrastructural in situ and in vitro immunologic characterization

L7 ANSWER 50 OF 76 LIFESCI COPYRIGHT 2006 CSA on STN
TI Eosinophil granule proteins activate human heart mast cells

L7 ANSWER 51 OF 76 Elsevier BIOBASE COPYRIGHT 2006 Elsevier Science B.V. on STN
TI The role of basophils in allergic disease

L7 ANSWER 52 OF 76 Elsevier BIOBASE COPYRIGHT 2006 Elsevier Science B.V. on STN DUPLICATE
TI Heterogeneity of human mast cells based on cytokine content

L7 ANSWER 53 OF 76 USPATFULL on STN
TI Hematopoietic cell specific transcriptional regulatory elements of serglycin and uses thereof

L7 ANSWER 54 OF 76 Elsevier BIOBASE COPYRIGHT 2006 Elsevier Science B.V. on STN DUPLICATE
TI Development of a new, more sensitive immunoassay for human tryptase: Use in systemic anaphylaxis

L7 ANSWER 55 OF 76 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 16
TI Tissue angiotensin II system in the human heart.

L7 ANSWER 56 OF 76 BIOTECHNO COPYRIGHT 2006 Elsevier Science B.V. on STN
TI Three-dimensional models of four mouse mast cell chymases. Identification of proteoglycan binding regions and protease-specific antigenic epitopes

L7 ANSWER 57 OF 76 BIOTECHNO COPYRIGHT 2006 Elsevier Science B.V. on STN
TI Translation and granule localization of mouse mast cell protease-5: Immunodetection with specific antipeptide Ig

L7 ANSWER 58 OF 76 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on

STN DUPLICATE 17
TI DIFFERENTIAL EXPRESSION OF SECRETORY GRANULE PROTEASES IN MOUSE MAST CELLS EXPOSED TO INTERLEUKIN 3 AND C-KIT LIGAND.

L7 ANSWER 59 OF 76 BIOTECHNO COPYRIGHT 2006 Elsevier Science B.V. on STN DUPLICATE
TI Cloning and characterization of the novel gene for mast cell carboxypeptidase A

L7 ANSWER 60 OF 76 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Mast cells and skin tumours.

L7 ANSWER 61 OF 76 BIOTECHNO COPYRIGHT 2006 Elsevier Science B.V. on STN
TI Continuous release of secretory granule proteoglycans from a cell strain derived from the bone marrow of a patient with diffuse cutaneous mastocytosis

L7 ANSWER 62 OF 76 BIOTECHNO COPYRIGHT 2006 Elsevier Science B.V. on STN DUPLICATE
TI Identification of aminopeptidase activity in the secretory granules of mouse mast cells

L7 ANSWER 63 OF 76 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 20
TI CYTOKINE MESSENGER RNA ARE PREFERENTIALLY INCREASED RELATIVE TO SECRETORY GRANULE PROTEIN MESSENGER RNA IN MOUSE BONE MARROW-DERIVED MAST CELLS THAT HAVE UNDERGONE IGE-MEDIATED ACTIVATION AND DEGRANULATION.

L7 ANSWER 64 OF 76 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI **LOCALIZATION** AND DISCHARGE OF **MAST CELL** SERINE **PROTEINASES** EVIDENCE OF COMPARTMENTALIZATION AND EXTERNALIZATION BY **SECRETORY GRANULES.**

L7 ANSWER 65 OF 76 CAPLUS COPYRIGHT 2006 ACS on STN
TI Rat mast cell tryptase

L7 ANSWER 66 OF 76 MEDLINE on STN DUPLICATE 21
TI Human mucus proteinase inhibitor (human MPI). Human seminal inhibitor I (HUSI-I), antileukoprotease (ALP), secretory leukocyte protease inhibitor (SLPI).

L7 ANSWER 67 OF 76 BIOTECHNO COPYRIGHT 2006 Elsevier Science B.V. on STN
TI Human skin chymotrypsin-like proteinase chymase. Subcellular localization to mast cell granules and interaction with heparin and other glycosaminoglycans

L7 ANSWER 68 OF 76 CAPLUS COPYRIGHT 2006 ACS on STN
TI Carboxypeptidase A in mouse mast cells. Identification, characterization, and use as a differentiation marker

L7 ANSWER 69 OF 76 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 22
TI DETECTION AND PARTIAL CHARACTERIZATION OF A HUMAN MAST CELL CARBOXYPEPTIDASE.

L7 ANSWER 70 OF 76 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 23
TI SUBSTRATE SPECIFICITY OF THE CHYMOTRYPSIN-LIKE PROTEASE IN SECRETORY GRANULES ISOLATED FROM RAT MAST CELLS.

L7 ANSWER 71 OF 76 LIFESCI COPYRIGHT 2006 CSA on STN
TI Substrate specificity of the chymotrypsin-like protease in secretory granules isolates from rat mast cells.

L7 ANSWER 72 OF 76 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 24
TI REGULATION OF TRYPTASE FROM HUMAN LUNG MAST CELLS BY HEPARIN STABILIZATION OF THE ACTIVE TETRAMER.

L7 ANSWER 73 OF 76 BIOTECHNO COPYRIGHT 2006 Elsevier Science B.V. on STN
TI Purification and characterization of protease-resistant secretory granule proteoglycans containing chondroitin sulfate Di-B and heparin-like glycosaminoglycans from rat basophilic leukemia cells

L7 ANSWER 74 OF 76 MEDLINE on STN DUPLICATE 25
TI **Localization** of **carboxypeptidase** A to the macromolecular heparin proteoglycan-protein complex in **secretory granules** of rat serosal **mast cells.**

L7 ANSWER 75 OF 76 BIOTECHNO COPYRIGHT 2006 Elsevier Science B.V. on STN
TI Collagens of basement membranes

L7 ANSWER 76 OF 76 MEDLINE on STN DUPLICATE 26
TI Enzymes of the mast cell granule.

=> d ibib abs l7 6 8 11 24 29 30 33 36 37 39 54 58 64 74 76

L7 ANSWER 6 OF 76 USPATFULL on STN
ACCESSION NUMBER: 2005:81467 USPATFULL
TITLE: Method to identify and analyze genes having modified expression in activated cells with secretory lysosomes
INVENTOR(S): Kabcenell, Alisa, Weston, CT, UNITED STATES
Li, Jun, Danbury, CT, UNITED STATES
Rajotte, Daniel, Danbury, CT, UNITED STATES
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, UNITED STATES, 06877-0368 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005069909	A1	20050331
APPLICATION INFO.:	US 2003-737465	A1	20031216 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-437239P	20021231 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MICHAEL P. MORRIS, BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P O BOX 368, RIDGEFIELD, CT, 06877-0368
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 949
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of identifying genes involved in the regulated secretion of cells having secretory lysosomes comprising the steps of:

a) exposing experimental cells to an activating agent;

b) preparing RNA from said experimental cells at one or more activation phases;

c) measuring the level of gene expression in the cells;

d) comparing the levels of gene expression of said experimental cells to the level of gene expression in control cells that have not been exposed

to an activating agent;

e) identifying genes that are up regulated or down regulated in said experimental cells relative to said control cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 8 OF 76 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:477401 CAPLUS
DOCUMENT NUMBER: 144:123728
TITLE: A role for cathepsin E in the processing of mast-cell carboxypeptidase A
AUTHOR(S): Henningsson, Frida; Yamamoto, Kenji; Saftig, Paul; Reinheckel, Thomas; Peters, Christoph; Knight, Stefan D.; Pejler, Gunnar
CORPORATE SOURCE: Department of Molecular Biosciences, The Biomedical Centre, Swedish University of Agricultural Sciences, Uppsala, 751 23, Swed.
SOURCE: Journal of Cell Science (2005), 118(9), 2035-2042
CODEN: JNCSAI; ISSN: 0021-9533
PUBLISHER: Company of Biologists Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Mast-cell carboxypeptidase A is stored in the secretory granule and is released, together with a range of other inflammatory mediators, upon mast-cell degranulation. Carboxypeptidase A, like all mast-cell proteases, is stored in the granule as an active enzyme (i.e. with its propeptide removed). Although the processing mechanisms for the other classes of mast-cell proteases (in particular the chymases) have been clarified to some extent, the processing of procarboxypeptidase A is poorly characterized. Here, we show that mast cells from mice lacking the aspartic protease cathepsin E display an accumulation of procarboxypeptidase A, indicating a defect in carboxypeptidase-A processing. By contrast, mast cells lacking cathepsins B, L or D have normal carboxypeptidase-A processing. Furthermore, recombinant cathepsin E was found to process recombinant procarboxypeptidase A in vitro, under conditions resembling those found in mast-cell granules. Immunohistochem. anal. revealed staining for cathepsin E in mast cells from normal mice but not in mast cells from mice lacking heparin, indicating that cathepsin E is bound to heparin proteoglycan within mast-cell granules. In accordance with this notion, affinity chromatog. showed that recombinant cathepsin E bound strongly to heparin under acidic conditions (the conditions prevailing in mast-cell granules) but not at neutral pH. Moreover, mast-cell degranulation resulted in the release of cathepsin E. Taken together, our results indicate that cathepsin E is located in mast-cell secretory granules in complex with heparin proteoglycans, and that it has a role in the processing of procarboxypeptidase A into active protease.
REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 76 USPATFULL on STN
ACCESSION NUMBER: 2004:107617 USPATFULL
TITLE: Methods and compositions for targeting secretory lysosomes
INVENTOR(S): Rajotte, Daniel, Danbury, CT, UNITED STATES
Kabcenell, Alisa, Weston, CT, UNITED STATES
PATENT ASSIGNEE(S): Boehringer Ingelheim Phamaceuticals, Inc., Ridgefield, CT, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004082017	A1	20040429	
APPLICATION INFO.:	US 2003-637887	A1	20030808	(10)

NUMBER DATE

PRIORITY INFORMATION: US 2002-403464P 20020814 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P O BOX 368, RIDGEFIELD, CT, 06877
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 720
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to methods and compositions for targeting proteins to secretory lysosomes. The invention further provides methods of use in drug screening assays, and methods of purifying secretory lysosomes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 24 OF 76 Elsevier BIOBASE COPYRIGHT 2006 Elsevier Science B.V. on STN DUPLICATE
ACCESSION NUMBER: 2003263162 ESBIOBASE
TITLE: IL-1 Induces Vesicular Secretion of IL-6 without Degranulation from Human Mast Cells
AUTHOR: Kandere-Grzybowska K.; Letourneau R.; Kempuraj D.; Donelan J.; Poplawski S.; Boucher W.; Athanassiou A.; Theoharides T.C.
CORPORATE SOURCE: Dr. T.C. Theoharides, Dept. of Pharmacol./Exp. Therapeut., Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, United States. E-mail: theoharis.theoharides@tufts.edu
SOURCE: Journal of Immunology, (01 OCT 2003), 171/9 (4830-4836), 59 reference(s) CODEN: JOIMA3 ISSN: 0022-1767
DOCUMENT TYPE: Journal; Article
COUNTRY: United States
LANGUAGE: English
SUMMARY LANGUAGE: English
AB FcεRI cross-linkage in **mast cells** results in release of **granule**-associated mediators, such as histamine and **proteases**, as well as the production of numerous cytokines, including IL-6. **Mast cells** have been increasingly implicated in inflammatory processes where explosive degranulation is not commonly observed. Here, we show that IL-1 stimulates **secretion** of IL-6 without release of the **granule**-associated **protease tryptase** in normal human umbilical cord blood-derived **mast cells** (hCBMCs). IL-6 **secretion** stimulated by IL-1 in hCBMCs is potentiated by priming with IL-4 and reflects the higher levels of IL-6 **secreted** from human leukemic **mast cell** line (HMC-1). Stimulating HMC-1 **cells** by both IL-1 and TNF-α results in synergistic **secretion** of IL-6. IL-6 is de novo synthesized, as its **secretion** is blocked by inhibitors of transcription or protein synthesis. IL-1 does not increase intracellular calcium ion levels in either hCBMCs or HMC-1 **cells**, and IL-6 stimulation proceeds in the absence of extracellular calcium ions. Ultrastructural Immunogold **localization** shows that IL-6 is excluded from the **secretory granules** and is compartmentalized in 40-to 80-nm vesicular structures. Selective **secretion** of IL-6 from **mast cells** appears distinct from degranulation and may contribute to the development of inflammation, where the importance of IL-6 has been recognized.

L7 ANSWER 29 OF 76 USPATFULL on STN
ACCESSION NUMBER: 2002:67207 USPATFULL
TITLE: Method for reducing or preventing the establishment,

growth or metastasis of cancer by administering indazole peptidomimetics PAR-1 antagonist and optionally PAR-2 antagonists

INVENTOR(S): D'Andrea, Michael, Cherry Hill, NJ, UNITED STATES
Derian, Claudia, Hatboro, PA, UNITED STATES
Woodrow, Hal Brent, Princeton, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002037860	A1	20020328
APPLICATION INFO.:	US 2001-865511	A1	20010525 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-603338, filed on 26 Jun 2000, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-141553P	19990629 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Page(s)
LINE COUNT: 2331
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB We have discovered a method of modifying the tumor cell microenvironment to reduce or prevent the establishment, growth or metastasis of malignant cells comprising administering to a patient having malignant cells a pharmaceutically effective amount of an indazole peptidomimetic PAR-1 inhibitor and optionally a PAR-2 inhibitor to prevent or reduce activation of normal cells within the tumor microenviroment. This method also has the effect in some patients of modulating the immune system to facilitate a more efficient immune response to malignant cells and maybe coupled with cytokine therapy and T-cell therapy to enhance the patient's immune response to the malignant cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 30 OF 76 USPATFULL on STN
ACCESSION NUMBER: 2002:238679 USPATFULL
TITLE: Natural product composition for decreasing IgE production and treating secondary allergic responses
INVENTOR(S): Hebert, Rolland, Seattle, WA, United States
Shanmugasundaram, Edayatimangalam Raja Bhavani, Chennai, INDIA
Shanmugasundaram, Kalathkal Radha, Chennai, INDIA
PATENT ASSIGNEE(S): Pharma Terra, Inc., Marcer Island, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6451354	B1	20020917
APPLICATION INFO.:	US 2000-696498		20001025 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-162038P	19991026 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Tate, Christopher R.
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 401

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A salt-spice-herbal composition known as Amrita Bindu that is clinically useful for reducing IgE production and treating secondary allergic responses is disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 33 OF 76 Elsevier BIOBASE COPYRIGHT 2006 Elsevier Science B.V. on STN DUPLICATE

ACCESSION NUMBER: 2002096388 ESBIOBASE
TITLE: Tissue-specific expression of mast cell granule serine proteinases and their role in inflammation in the lung and gut
AUTHOR: Miller H.R.P.; Pemberton A.D.
CORPORATE SOURCE: H.R.P. Miller, W. Trust Ctr. Res. Comp. Resp. Med., Faculty of Veterinary Medicine, University of Edinburgh, Roslin, Midlothian, United Kingdom. E-mail: hrpm@staffmail.ed.ac.uk
SOURCE: Immunology, (2002), 105/4 (375-390), 212 reference(s) CODEN: IMMUAM ISSN: 0019-2805
DOCUMENT TYPE: Journal; General Review
COUNTRY: United Kingdom
LANGUAGE: English
SUMMARY LANGUAGE: English

AB Serine **proteinases** with trypsin-like (**tryptase**) and chymotrypsin-like (**chymase**) properties are major constituents of **mast cell granules.** Several tetrameric **tryptases** with differing specificities have been characterized in humans, but only a single **chymase.** In other species there are larger families of **chymases** with distinct and narrow proteolytic specificities. Expression of **chymases** and **tryptases** varies between tissues. Human pulmonary and gastrointestinal **mast cells** express **chymase** at lower levels than **tryptase**, whereas rodent and ruminant gastrointestinal **mast cells** express uniquely mucosa-specific **chymases. Local** and systemic release of **chymases** and **tryptases** can be quantified by immunoassay, providing highly specific markers of **mast cell** activation. The expression and constitutive extra-**cellular secretion** of the mucosa-specific **chymase**, mouse **mast cell proteinase** -1 (mMCP-1)., is regulated by transforming growth factor-β.sub.1 (TGF-β.sub.1) in vitro, but it is not clear how the differential expression of **chymases** and **tryptases** is regulated in other species. Few native inhibitors have been identified for **tryptases** but the tetramers dissociate into inactive subunits in the absence of heparin. **Chymases** are variably inhibited by plasma **proteinase** inhibitors and by **secretory** leucocyte **protease** inhibitor (SLPI) that is expressed in the airways. **Tryptases** and **chymases** promote vascular permeability via indirect and possibly direct mechanisms. They contribute to tissue remodelling through selective proteolysis of matrix proteins and through activation of **proteinase**-activated receptors and of matrix metalloproteinases. **Chymase** may modulate vascular tissues through its ability to process angiotensin-I to angiotensin-II. Mucosa-specific **chymases** promote epithelial permeability and are involved in the immune expulsion of intestinal nematodes. Importantly, **granule proteinases** released extracellularly contribute to the recruitment of inflammatory **cells** and may thus be involved in innate responses to infection.

L7 ANSWER 36 OF 76 Elsevier BIOBASE COPYRIGHT 2006 Elsevier Science B.V. on STN

ACCESSION NUMBER: 2001042842 ESBIOBASE
TITLE: Secretory granules of mast cells accumulate mature and

immature MHC class II molecules
AUTHOR: Vincent-Schneider H.; Thery C.; Mazzeo D.; Tenza D.; Raposo G.; Bonnerot C.
CORPORATE SOURCE: C. Bonnerot, INSERM, Institut Curie, 12 rue Lhomond, 75005 Paris, France.
E-mail: bonnerot@curie.fr
SOURCE: Journal of Cell Science, (2001), 114/2 (323-334), 43 reference(s)
CODEN: JNCSAI ISSN: 0021-9533
DOCUMENT TYPE: Journal; Article
COUNTRY: United Kingdom
LANGUAGE: English
SUMMARY LANGUAGE: English
AB Bone marrow-derived **mast cells** as well as dendritic **cells**, macrophages and B lymphocytes express major histocompatibility complex (MHC) class II molecules. In **mast cells**, the majority of MHC class II molecules reside in intracellular **cell** type-specific compartments, **secretory granules.** To understand the molecular basis for the **localisation** of MHC class II molecules in **secretory granules**, MHC class II molecules were expressed, together with the invariant chain, in the **mast cell** line, RBL-2H3. Using electron and confocal microscopy, we observed that in RBL-2H3 **cells**, mature and immature class II molecules accumulate in **secretory granules.** Two particular features of class II transport accounted for this intracellular **localization**: first, a large fraction of newly synthesized MHC class II molecules remained associated with invariant chain fragments. This defect, resulting in a slower rate of MHC class II maturation, was ascribed to a low **cathepsin** S activity. Second, although a small fraction of class II dimers matured (i.e. became free of invariant chain), allowing their association with antigenic peptides, they were retained in **secretory granules.** As a consequence of this intracellular **localization**, **cell** surface expression of class II molecules was strongly increased by **cell** activation stimuli which induced the release of the contents of **secretory granules.** Our results suggest that antigen presentation, and thereby antigen specific T **cell** stimulation, are regulated in **mast cells** by stimuli which induce **mast cell** activation.

L7 ANSWER 37 OF 76 MEDLINE on STN
ACCESSION NUMBER: 2002229917 MEDLINE
DOCUMENT NUMBER: PubMed ID: 11967791
TITLE: Role of chymase on vascular proliferation.
AUTHOR: Miyazaki M; Takai S
SOURCE: Journal of the renin-angiotensin-aldosterone system : JRAAS, (2000 Mar) Vol. 1, No. 1, pp. 23-6. Ref: 48
Journal code: 100971636. ISSN: 1470-3203.
PUB. COUNTRY: England: United Kingdom
DOCUMENT TYPE: Editorial
General Review; (REVIEW)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200206
ENTRY DATE: Entered STN: 23 Apr 2002
Last Updated on STN: 11 Jun 2002
Entered Medline: 6 Jun 2002
AB In the normal state, vascular ACE regulates **local** angiotensin II formation and plays a crucial role in the regulation of blood pressure, whereas **chymase** is stored in **secretory granules** in **mast cells** and has no enzymatic effects such as angiotensin II-forming activity. Chymase has a maximal activity immediately upon release into the extracellular matrix in vascular tissues after mast cells have been activated by a strong stimulus

such as experienced by catheter-injured and grafted vessels. Therefore, chymase plays an important role in forming local angiotensin II when vascular tissues are injured, and inhibition of chymase may be useful for preventing vascular proliferation in grafted vessels and after PTCA (Figure 6).

L7 ANSWER 39 OF 76 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 7
ACCESSION NUMBER: 2000:226823 CAPLUS
DOCUMENT NUMBER: 132:332419
TITLE: Latexin, a carboxypeptidase A inhibitor, is expressed in rat peritoneal mast cells and is associated with granular structures distinct from secretory granules and lysosomes
AUTHOR(S): Uratani, Yoshihiko; Takiguchi-Hayashi, Keiko; Miyasaka, Nobuhiko; Sato, Michio; Jin, Ming-Hao; Arimatsu, Yasuyoshi
CORPORATE SOURCE: Mitsubishi Kasei Institute of Life Sciences, Tokyo, 194-8511, Japan
SOURCE: Biochemical Journal (2000), 346(3), 817-826
CODEN: BIJOAK; ISSN: 0264-6021
PUBLISHER: Portland Press Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Latexin, a protein possessing inhibitory activity against rat carboxypeptidase A1 (CPA1) and CPA2, is expressed in a neuronal subset in the cerebral cortex and cells in other neural and non-neural tissues of rat. Although latexin also inhibits mast-cell CPA (MCCPA), the expression of latexin in rat mast cells has not previously been confirmed. In the present study we examined the expression and subcellular localization of latexin in rat peritoneal mast cells. Western blot and reverse-transcriptase mediated PCR analyses showed that latexin was contained and expressed in the rat peritoneal mast cells. Immunocytochem., latexin immunofluorescence was localized on granular structures distinct from MCCPA-, histamine- or cathepsin D-immuno-pos. granules. Immunoelectron microscopy revealed that latexin was associated with a minority population of granules. The latexin-associated granules were separated from MCCPA- or histamine-containing granules on a self-generating d. gradient of polyvinylpyrrolidone-coated silica-gel particles (Percoll). Treatments with high ionic strength and heparinase released latexin from the granules, suggesting that latexin is non-covalently associated with a heparin-like component of the granules. MCCPA and histamine were released from the mast cells after non-immunol. and immunol. stimulation with compound 48/80, A23187 and anti-IgE antibody, whereas latexin was not released. These results show that latexin is synthesized in rat peritoneal mast cells and suggest that it is associated with a unique type of intracellular granules distinct from MCCPA- and histamine-containing secretory granules and lysosomes.
REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 54 OF 76 Elsevier BIOBASE COPYRIGHT 2006 Elsevier Science B.V. on STN DUPLICATE
ACCESSION NUMBER: 1994121105 ESBIOBASE
TITLE: Development of a new, more sensitive immunoassay for human tryptase: Use in systemic anaphylaxis
AUTHOR: Schwartz L.B.; Bradford T.R.; Rouse C.; Irani A.-M.; Rasp G.; Van Der Zwan J.K.; Van Der Linden P.-W.G.
CORPORATE SOURCE: L.B. Schwartz, Virginia Commonwealth University, MCV Box 263, Richmond, VA 23298, United States.
SOURCE: Journal of Clinical Immunology, (1994), 14/3 (190-204)
CODEN: JCIMDO ISSN: 0271-9142
DOCUMENT TYPE: Journal; Article
COUNTRY: United States
LANGUAGE: English
SUMMARY LANGUAGE: English

AB **Tryptase**, a neutral **protease**, is selectively concentrated in the **secretory granules** of human **mast cells**, and its release into the circulation serves as a clinical marker of **mast cell** activation. The current study describes a new, more sensitive ELISA utilizing a newly developed, mouse monoclonal IgG1 antibody for capture called B12 and capable of detecting **tryptase** in normal plasma and serum. The greater sensitivity of the new immunoassay results in part from a greater portion of **tryptase** being detected. Mean levels of **tryptase** in serum from normal subjects from Richmond, Virginia (4.9 ng/ml; n = 56), Munich, Germany (3.8 ng/ml; n = 19), and Amersfoort, The Netherlands (1.9 ng/ml; n = 8) were as indicated. In 62 subjects with ongoing allergic rhinitis, **tryptase** levels were no different in serum than for 19 normal controls, indicating that **local mast cell** activation is not necessarily reflected in the circulation. In 61 subjects sensitive to honey bee or yellow jacket venom by history, the 17 destined to have a severe, hypotensive response to a sting challenge had higher levels of **tryptase** at baseline than mild reactors, nonreactors, and controls, suggesting that baseline levels of **tryptase** may predict the severity of the clinical response to allergen in sensitive subjects.

L7 ANSWER 58 OF 76 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 17

ACCESSION NUMBER: 1992:276752 BIOSIS
DOCUMENT NUMBER: PREV199294001402; BA94:1402
TITLE: DIFFERENTIAL EXPRESSION OF SECRETORY GRANULE PROTEASES IN MOUSE MAST CELLS EXPOSED TO INTERLEUKIN 3 AND C-KIT LIGAND.
AUTHOR(S): GURISH M F [Reprint author]; GHILDYAL N; MCNEIL H P; AUSTEN K F; GILLIS S; STEVENS R L
CORPORATE SOURCE: DEP MED, HARVARD MED SCH, SEELEY G MUDD BUILD, ROOM 625, 250 LONGWOOD AVE, BOSTON, MASS 02115, USA
SOURCE: Journal of Experimental Medicine, (1992) Vol. 175, No. 4, pp. 1003-1012.
CODEN: JEMEAV. ISSN: 0022-1007.
DOCUMENT TYPE: Article
FILE SEGMENT: BA
LANGUAGE: ENGLISH
ENTRY DATE: Entered STN: 10 Jun 1992
Last Updated on STN: 10 Jun 1992

AB It is now established that the subclass of **mast cells** (MC) that reside in mucosal and serosal environments can be distinguished from one another in terms of their expression of specific **secretory granule-localized proteases** and proteoglycans. Further, the hematopoietic- and connective tissue-derived cytokines that regulate expression of the genes that encode these constituents of the granule can now be identified using recently developed gene-specific probes and recombinant cytokines. When bone marrow-derived MC (BMMC) were developed with recombinant interleukin 3 (rIL-3) and maintained with this cytokine in the absence or presence of recombinant c-kit ligand (rKL), they remained safranin-, produced almost no 35S-labled heparin proteoglycans, and contained greater levels of mouse MC protease (MMCP) -5 mRNA and mast cell carboxypeptidase A (MC-CPA) mRNA than MMCP-6 mRNA. They did not contain MMCP-4 or -2 mRNA, genes expressed late in the differentiation of progenitor cells into serosal and mucosal MCs, respectively. In contrast, BMMC developed with rKL alone or by sequential culture in medium containing rIL-3 followed by rKL expressed high levels of MMCP-4 and -6 mRNA, as well as the transcripts that encode MMCP-5 and MC-CPA. Although rKL-developed BMMC were safranin+ and produced substantial amounts of 35S-labeled heparin proteoglycans, they contained only minimal amounts of histamine and MC-CPA enzymatic activity relative to serosal MC. These are the first studies to charactrize the transcriptional granule phenotype of a population of BMMC derived using any recombinant cytokine, to demonstrate a dissociation between histochemical staining and granule maturation, and to demonstrate

antagonistic regulation of late expressed protease genes by a cytokine.

L7 ANSWER 64 OF 76 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 1992:88484 BIOSIS
DOCUMENT NUMBER: PREV199242040759; BR42:40759
TITLE: **LOCALIZATION** AND DISCHARGE OF **MAST CELL** SERINE **PROTEINASES** EVIDENCE OF COMPARTMENTALIZATION AND EXTERNALIZATION BY **SECRETORY GRANULES.**
AUTHOR(S): WHITAKER D [Reprint author]; SCHECHTER N M; LAZARUS G S; MURPHY G F
CORPORATE SOURCE: DEP DEMATOL, UNIV PENNSYLVANIA MED SCH, PHILADELPHIA, PA 19104, USA
SOURCE: Journal of Cell Biology, (1991) Vol. 115, No. 3 PART 2, pp. 303A.
Meeting Info.: ABSTRACTS OF PAPERS PRESENTED AT THE THIRTY-FIRST ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CELL BIOLOGY, BOSTON, MASSACHUSETTS, USA, DECEMBER 8-12, 1991. J CELL BIOL.
CODEN: JCLBA3. ISSN: 0021-9525.
DOCUMENT TYPE: Conference; (Meeting)
FILE SEGMENT: BR
LANGUAGE: ENGLISH
ENTRY DATE: Entered STN: 4 Feb 1992
Last Updated on STN: 5 Feb 1992

L7 ANSWER 74 OF 76 MEDLINE on STN DUPLICATE 25

ACCESSION NUMBER: 82121151 MEDLINE
DOCUMENT NUMBER: PubMed ID: 6799569
TITLE: **Localization** of **carboxypeptidase** A to the macromolecular heparin proteoglycan-protein complex in **secretory granules** of rat serosal **mast cells.**
AUTHOR: Schwartz L B; Riedel C; Schratz J J; Austen K F
CONTRACT NUMBER: AI-07722 (NIAID)
AI-10356 (NIAID)
HL-17382 (NHLBI)
+
SOURCE: Journal of immunology (Baltimore, Md. : 1950), (1982 Mar) Vol. 128, No. 3, pp. 1128-33.
Journal code: 2985117R. ISSN: 0022-1767.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 198204
ENTRY DATE: Entered STN: 17 Mar 1990
Last Updated on STN: 3 Mar 2000
Entered Medline: 20 Apr 1982

L7 ANSWER 76 OF 76 MEDLINE on STN DUPLICATE 26

ACCESSION NUMBER: 80228988 MEDLINE
DOCUMENT NUMBER: PubMed ID: 6771334
TITLE: Enzymes of the mast cell granule.
AUTHOR: Schwartz L B; Austen K F
SOURCE: The Journal of investigative dermatology, (1980 May) Vol. 74, No. 5, pp. 349-53.
Journal code: 0426720. ISSN: 0022-202X.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198009
ENTRY DATE: Entered STN: 15 Mar 1990

Last Updated on STN: 15 Mar 1990
Entered Medline: 26 Sep 1980

AB Rat mast cell granules contain a spectrum of enzymes as established by histochemical techniques and subcellular fractionation. However, 35% of the beta-glucuronidase, 30% of the beta-D-galactosidase, 14% of the beta-hexosaminidase and all of the acid phosphatase is not available for immunologic release from purified rat serosal mast cells, suggesting the presence of nonsecretory lysosomes containing these acid hydrolases. On the other hand, immunologic release of the majority of **chymase**, beta-hexosaminidase, beta-glucuronidase, beta-D-galactosidase, and arylsulfatase A occurs in parallel with histamine and thereby **localizes** these substances to the rat **mast cell secretory granule.** A molecular model of the secretory granule in the resting mast cell can now be constructed in which heparin proteoglycan is the granule matrix to which chymase and probably other proteins are ionically bound. Inhibition of chymase by serotonin stored in its active site and of chymase and acid hydrolases by their interaction with heparin probably occurs. Histamine is stored by ionic linkage to carboxyl groups of protein and heparin. Micromolar amounts of heparin glycosaminoglycans, histamine, serotonin, chymase, beta-D-hexosaminidase, beta-glucuronidase, and arylsulfatase A in secretory granules of 10(6) mast cells are 0.7--1.3 x 10(-3), 70--220 x 10(-3), 0.9--28 x 10(-3), 0.2--0.5 x 10(-3), 0.9--2.7 x 10(-6), 0.1--0.3 x 10(-6) and less than 8 x 10(-6), respectively. In addition, the total protein available for calcium ionophore-induced release from 10(6) rat mast cells is about 60 microgram, indicating that less than 50% of the granule protein can be accounted for. Recognition that mast cell secretory granules contain acid hydrolases indicates that they are modified lysosomes; their special intracellular and extracellular functions are dictated by the associated novel constituents and the stimulus for activation.

=> s l7 and fus?
L8 27 L7 AND FUS?

=> d ti l8 1-28

L8 ANSWER 1 OF 27 USPATFULL on STN
TI RT-PCR-based cloning of the human beta-amyloid precursor protein gene and the construction of its expression plasmids

L8 ANSWER 2 OF 27 USPATFULL on STN
TI Novel inhibitors of chymase

L8 ANSWER 3 OF 27 USPATFULL on STN
TI Cancer treatment methods using selected antibodies to aminophospholipids

L8 ANSWER 4 OF 27 USPATFULL on STN
TI Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids

L8 ANSWER 5 OF 27 USPATFULL on STN
TI Method to identify and analyze genes having modified expression in activated cells with secretory lysosomes

L8 ANSWER 6 OF 27 USPATFULL on STN
TI Lp mammalian proteins; related reagents

L8 ANSWER 7 OF 27 USPATFULL on STN
TI Methods and compositions for targeting secretory lysosomes

L8 ANSWER 8 OF 27 USPATFULL on STN
TI Purified proenzyme of dipeptidyl peptidase i (pro-dppi)

L8 ANSWER 9 OF 27 USPATFULL on STN

TI Proteins and nucleic acids encoding same

L8 ANSWER 10 OF 27 USPATFULL on STN
TI Novel polypeptides and nucleic acids encoding same

L8 ANSWER 11 OF 27 USPATFULL on STN
TI Novel polypeptides and nucleic acids encoding same

L8 ANSWER 12 OF 27 USPATFULL on STN
TI Novel polypeptides and nucleic acids encoding same

L8 ANSWER 13 OF 27 USPATFULL on STN
TI Novel polypeptides and nucleic acids encoding same

L8 ANSWER 14 OF 27 USPATFULL on STN
TI Novel proteins and nucleic acids encoding same

L8 ANSWER 15 OF 27 USPATFULL on STN
TI Interventions to mimic the effects of calorie restriction

L8 ANSWER 16 OF 27 USPATFULL on STN
TI Novel polypeptides and nucleic acids encoding same

L8 ANSWER 17 OF 27 USPATFULL on STN
TI Novel polypeptides and nucleic acids encoding same

L8 ANSWER 18 OF 27 USPATFULL on STN
TI Natural product composition for decreasing IgE production and treating secondary allergic responses

L8 ANSWER 19 OF 27 USPATFULL on STN
TI Method for reducing or preventing the establishment, growth or metastasis of cancer by administering benzimidazolone peptidomimetics PAR-1 antagonist and optionally PAR-2 antagonists

L8 ANSWER 20 OF 27 USPATFULL on STN
TI Method for reducing or preventing the establishment, growth or metastasis of cancer by administering indole peptidomimetics PAR-1 antagonist and optionally PAR-2 antagonists

L8 ANSWER 21 OF 27 USPATFULL on STN
TI Interventions to mimic the effects of calorie restriction

L8 ANSWER 22 OF 27 USPATFULL on STN
TI Method for reducing or preventing the establishment, growth or metastasis of cancer by administering PAR-1 and optionally PAR-2 antagonists

L8 ANSWER 23 OF 27 USPATFULL on STN
TI Method for reducing or preventing the establishment, growth or metastasis of cancer by administering indazole peptidomimetics PAR-1 antagonist and optionally PAR-2 antagonists

L8 ANSWER 24 OF 27 USPATFULL on STN
TI Phospholipase D gene

L8 ANSWER 25 OF 27 USPATFULL on STN
TI Mast cell protease that cleaves fibrinogen

L8 ANSWER 26 OF 27 USPATFULL on STN
TI Hematopoietic cell specific transcriptional regulatory elements of serglycin and uses thereof

L8 ANSWER 27 OF 27 Elsevier BIOBASE COPYRIGHT 2006 Elsevier Science B.V. on STN

TI Isolation of Mast Cell Secretory Lysosomes Using Flow Cytometry

=> s l5 and mast?
L9 181 L5 AND MAST?

=> s l9 and fus?
L10 60 L9 AND FUS?

=> dup rem l10
PROCESSING COMPLETED FOR L10
L11 59 DUP REM L10 (1 DUPLICATE REMOVED)

=> d ti l11 1-59

L11 ANSWER 1 OF 59 USPATFULL on STN
TI Vp2-modified raav vector compositions and uses therefor

L11 ANSWER 2 OF 59 USPATFULL on STN
TI Raav expression systems for genetic modification of specific capsid proteins

L11 ANSWER 3 OF 59 USPATFULL on STN
TI RT-PCR-based cloning of the human beta-amyloid precursor protein gene and the construction of its expression plasmids

L11 ANSWER 4 OF 59 USPATFULL on STN
TI Methods and compositions for diagnosing and monitoring transplant rejection

L11 ANSWER 5 OF 59 USPATFULL on STN
TI Bioinformatically detectable group of novel regulatory genes and uses thereof

L11 ANSWER 6 OF 59 USPATFULL on STN
TI Compositions and methods for treatment of infectious and inflammatory diseases

L11 ANSWER 7 OF 59 USPATFULL on STN
TI Cystatin C as an antagonist of TGF-beta and methods related thereto

L11 ANSWER 8 OF 59 USPATFULL on STN
TI Non-natural ribonuclease conjugates as cytotoxic agents

L11 ANSWER 9 OF 59 USPATFULL on STN
TI Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases

L11 ANSWER 10 OF 59 USPATFULL on STN
TI Allogeneic vaccine and methods to synthesize same

L11 ANSWER 11 OF 59 USPATFULL on STN
TI Therapeutic use of factor XI

L11 ANSWER 12 OF 59 USPATFULL on STN
TI Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer

L11 ANSWER 13 OF 59 USPATFULL on STN
TI Novel inhibitors of chymase

L11 ANSWER 14 OF 59 USPATFULL on STN
TI Treatment of vascular dysfunction and alzheimer's disease

L11 ANSWER 15 OF 59 USPATFULL on STN

TI Allogeneic vaccine and methods to synthesize same

L11 ANSWER 16 OF 59 USPATFULL on STN
TI Cancer treatment methods using selected antibodies to aminophospholipids

L11 ANSWER 17 OF 59 USPATFULL on STN
TI Compositions isolated from bovine mammary gland and methods for their use

L11 ANSWER 18 OF 59 USPATFULL on STN
TI Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids

L11 ANSWER 19 OF 59 USPATFULL on STN
TI PROTEIN THAT MODULATES THE STABILITY OF TRANSCRIPTIONAL REGULATORY COMPLEXES REGULATING NUCLEAR HORMONE RECEPTOR ACTIVITY, DNA ENCODING SAME, AND ANTIBODIES THERETO

L11 ANSWER 20 OF 59 USPATFULL on STN
TI Method of identifying modulators of presenilin

L11 ANSWER 21 OF 59 USPATFULL on STN
TI Method to identify and analyze genes having modified expression in activated cells with secretory lysosomes

L11 ANSWER 22 OF 59 USPATFULL on STN
TI Vesicle-associated proteins

L11 ANSWER 23 OF 59 USPATFULL on STN
TI Diagnostics and therapeutics for restenosis

L11 ANSWER 24 OF 59 USPATFULL on STN
TI Methods and compositions for the inhibition of cathepsins

L11 ANSWER 25 OF 59 USPATFULL on STN
TI Lp mammalian proteins; related reagents

L11 ANSWER 26 OF 59 USPATFULL on STN
TI Methods and compositions for targeting secretory lysosomes

L11 ANSWER 27 OF 59 USPATFULL on STN
TI Novel nucleic acids and secreted polypeptides

L11 ANSWER 28 OF 59 USPATFULL on STN
TI Purified proenzyme of dipeptidyl peptidase i (pro-dppi)

L11 ANSWER 29 OF 59 USPATFULL on STN
TI Proteins and nucleic acids encoding same

L11 ANSWER 30 OF 59 USPATFULL on STN
TI Polynucleotide encoding a novel cysteine protease of the calpain superfamily, Protease-42

L11 ANSWER 31 OF 59 USPATFULL on STN
TI Novel polypeptides and nucleic acids encoding same

L11 ANSWER 32 OF 59 USPATFULL on STN
TI Selections of genes and methods of using the same for diagnosis and for targeting the therapy of select cancers

L11 ANSWER 33 OF 59 USPATFULL on STN
TI Endometrial genes in endometrial disorders

L11 ANSWER 34 OF 59 USPATFULL on STN
TI Methods of diagnosis of ovarian cancer, compositions and methods of

screening for modulators of ovarian cancer

L11 ANSWER 35 OF 59 USPATFULL on STN
TI Novel full-length cDNA

L11 ANSWER 36 OF 59 USPATFULL on STN
TI Methods of treating vascular disease associated with cystatin C deficiency

L11 ANSWER 37 OF 59 USPATFULL on STN
TI Diagnostics and therapeutics for restenosis

L11 ANSWER 38 OF 59 USPATFULL on STN
TI Novel polypeptides and nucleic acids encoding same

L11 ANSWER 39 OF 59 USPATFULL on STN
TI Novel polypeptides and nucleic acids encoding same

L11 ANSWER 40 OF 59 USPATFULL on STN
TI Novel polypeptides and nucleic acids encoding same

L11 ANSWER 41 OF 59 USPATFULL on STN
TI Compositions and methods for treatment of infectious and inflammatory diseases

L11 ANSWER 42 OF 59 USPATFULL on STN
TI Novel proteins and nucleic acids encoding same

L11 ANSWER 43 OF 59 USPATFULL on STN
TI Interventions to mimic the effects of calorie restriction

L11 ANSWER 44 OF 59 USPATFULL on STN
TI Novel polypeptides and nucleic acids encoding same

L11 ANSWER 45 OF 59 USPATFULL on STN
TI Novel polypeptides and nucleic acids encoding same

L11 ANSWER 46 OF 59 USPATFULL on STN
TI Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases

L11 ANSWER 47 OF 59 Elsevier BIOBASE COPYRIGHT 2006 Elsevier Science B.V. on STN DUPLICATE
TI Isolation of **Mast** Cell Secretory Lysosomes Using Flow Cytometry

L11 ANSWER 48 OF 59 USPATFULL on STN
TI Nucleic acids, proteins and antibodies

L11 ANSWER 49 OF 59 USPATFULL on STN
TI 33449, a human protease family member and uses thereof

L11 ANSWER 50 OF 59 USPATFULL on STN
TI Method for reducing or preventing the establishment, growth or metastasis of cancer by administering benzimidazolone peptidomimetics PAR-1 antagonist and optionally PAR-2 antagonists

L11 ANSWER 51 OF 59 USPATFULL on STN
TI Method for reducing or preventing the establishment, growth or metastasis of cancer by administering indole peptidomimetics PAR-1 antagonist and optionally PAR-2 antagonists

L11 ANSWER 52 OF 59 USPATFULL on STN
TI Method for reducing or preventing the establishment, growth or metastasis of cancer by administering PAR-1 and optionally PAR-2 antagonists

L11 ANSWER 53 OF 59 USPATFULL on STN
TI Method for reducing or preventing the establishment, growth or metastasis of cancer by administering indazole peptidomimetics PAR-1 antagonist and optionally PAR-2 antagonists

L11 ANSWER 54 OF 59 USPATFULL on STN
TI Natural product composition for decreasing IgE production and treating secondary allergic responses

L11 ANSWER 55 OF 59 USPATFULL on STN
TI Bone remodeling genes

L11 ANSWER 56 OF 59 USPATFULL on STN
TI Interventions to mimic the effects of calorie restriction

L11 ANSWER 57 OF 59 USPATFULL on STN
TI Phospholipase D gene

L11 ANSWER 58 OF 59 USPATFULL on STN
TI **Mast** cell protease that cleaves fibrinogen

L11 ANSWER 59 OF 59 USPATFULL on STN
TI Hematopoietic cell specific transcriptional regulatory elements of serglycin and uses thereof

=> d l11 ibib abs 21 47 53 58

L11 ANSWER 21 OF 59 USPATFULL on STN

ACCESSION NUMBER:	2005:81467 USPATFULL
TITLE:	Method to identify and analyze genes having modified expression in activated cells with secretory lysosomes
INVENTOR(S):	Kabcenell, Alisa, Weston, CT, UNITED STATES Li, Jun, Danbury, CT, UNITED STATES Rajotte, Daniel, Danbury, CT, UNITED STATES
PATENT ASSIGNEE(S):	Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, UNITED STATES, 06877-0368 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005069909	A1	20050331
APPLICATION INFO.:	US 2003-737465	A1	20031216 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-437239P	20021231 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	MICHAEL P. MORRIS, BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P O BOX 368, RIDGEFIELD, CT, 06877-0368
NUMBER OF CLAIMS:	23
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	5 Drawing Page(s)
LINE COUNT:	949

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of identifying genes involved in the regulated secretion of cells having secretory lysosomes comprising the steps of:

a) exposing experimental cells to an activating agent;

b) preparing RNA from said experimental cells at one or more activation phases;

c) measuring the level of gene expression in the cells;

d) comparing the levels of gene expression of said experimental cells to the level of gene expression in control cells that have not been exposed to an activating agent;

e) identifying genes that are up regulated or down regulated in said experimental cells relative to said control cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 47 OF 59 Elsevier BIOBASE COPYRIGHT 2006 Elsevier Science B.V. on STN DUPLICATE

ACCESSION NUMBER: 2003312729 ESBIOBASE
TITLE: Isolation of **Mast** Cell Secretory Lysosomes Using Flow Cytometry
AUTHOR: Rajotte D.; Stearns C.D.; Kabcenell A.K.
CORPORATE SOURCE: Dr. D. Rajotte, Department of Biology, Boehringer Ingelheim Pharmaceuticals, Research and Development Center, 900 Ridgebury Road, Ridgefield, CT 06877, United States.
E-mail: drajotte@rdg.boehringer-ingelheim.com
SOURCE: Cytometry Part A, (2003), 55/2 (94-101), 26 reference(s)
CODEN: CPAYAV ISSN: 0196-4763
DOCUMENT TYPE: Journal; Article
COUNTRY: United States
LANGUAGE: English
SUMMARY LANGUAGE: English

AB Background: **Mast cells** are specialized **secretory cells** of the immune system. Through exocytosis of their **secretory lysosomes** and **secretory granules, mast cells** release biologically active substances such as histamine and **proteases. Mast cell secretory granules** have been studied extensively but much less attention has been given to **secretory lysosomes.** Studies on **mast cell secretory lysosomes** are limited by the lack of selective markers and the difficulty to isolate this organelle from conventional **lysosomes.** Our goal was to develop better tools to study **secretory lysosomes.** Methods: We engineered a rat **mast cell** line over expressing a rat **mast cell protease** (RMCP) tagged with a red fluorescent protein (RMCP-DsRed). We used single organelle flow analysis (SOFA) to detect fluorescently labeled **secretory lysosomes.** The labeled organelles were then sorted using the fluorescence-assisted organelle sorting (FAOS) method. Results: We show that the RMCP-DsRed **fusion** protein selectively **localizes** to the **lysosomal** compartment and is exocytosed upon activation, confirming its **localization** in **secretory lysosomes. Lysosomal** fractions from **cells** expressing the RMCP-DsRed **fusion** were analyzed by SOFA and a specific population of **secretory lysosome** was identified. Finally, we sorted **secretory lysosomes** and showed that the sorted material had a higher specific activity for the compartment marker hexosaminidase than a sample obtained by conventional methods. Conclusions: Our work further demonstrates the usefulness of flow cytometry to study **cellular** organelles, and provides new tools to better understand the physiology of **secretory lysosomes.** .COPYRGT. 2003 Wiley-Liss, Inc.

L11 ANSWER 53 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2002:67207 USPATFULL
TITLE: Method for reducing or preventing the establishment, growth or metastasis of cancer by administering

indazole peptidomimetics PAR-1 antagonist and optionally PAR-2 antagonists

INVENTOR(S): D'Andrea, Michael, Cherry Hill, NJ, UNITED STATES
Derian, Claudia, Hatboro, PA, UNITED STATES
Woodrow, Hal Brent, Princeton, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002037860	A1	20020328
APPLICATION INFO.:	US 2001-865511	A1	20010525 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-603338, filed on 26 Jun 2000, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-141553P	19990629 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Page(s)
LINE COUNT: 2331
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB We have discovered a method of modifying the tumor cell microenvironment to reduce or prevent the establishment, growth or metastasis of malignant cells comprising administering to a patient having malignant cells a pharmaceutically effective amount of an indazole peptidomimetic PAR-1 inhibitor and optionally a PAR-2 inhibitor to prevent or reduce activation of normal cells within the tumor microenviroment. This method also has the effect in some patients of modulating the immune system to facilitate a more efficient immune response to malignant cells and maybe coupled with cytokine therapy and T-cell therapy to enhance the patient's immune response to the malignant cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 58 OF 59 USPATFULL on STN
ACCESSION NUMBER: 1999:128398 USPATFULL
TITLE: **Mast** cell protease that cleaves fibrinogen
INVENTOR(S): Stevens, Richard L., Sudbury, MA, United States
PATENT ASSIGNEE(S): Brigham and Womens's Hospital, Inc., Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5968782		19991019
APPLICATION INFO.:	US 1997-978404		19971125 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-32354P	19961204 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Moore, William W.
LEGAL REPRESENTATIVE: Wolf, Greenfield & Sacks, P.C.
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 3794

AB Compositions containing a Trypson-like serine protease from **mast** cells ("tryptase-7") are provided. The compositions are useful for treating blood clot formation in vitro and in in vitro. Also provided is a novel bioengineering method to produce the tryptase-7 and other serine

proteases in active form and in large quantities.

=> d his full

(FILE 'HOME' ENTERED AT 21:54:17 ON 02 JUN 2006)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 21:54:43 ON 02 JUN 2006

SEA SECRET?(S)(LYSOS? OR GRANUL?)

84	FILE ADISCTI
35	FILE ADISINSIGHT
28	FILE ADISNEWS
664	FILE AGRICOLA
11	FILE ANABSTR
1	FILE ANTE
8	FILE AQUALINE
1121	FILE AQUASCI
444	FILE BIOENG
16593	FILE BIOSIS
627	FILE BIOTECHABS
627	FILE BIOTECHDS
6865	FILE BIOTECHNO
3367	FILE CABA
13868	FILE CAPLUS
46	FILE CEABA-VTB
6	FILE CIN
234	FILE CONFSCI
10	FILE CROPU
193	FILE DDFB
600	FILE DDFU
2057	FILE DGENE
920	FILE DISSABS
193	FILE DRUGB
1247	FILE DRUGU
120	FILE EMBAL
13368	FILE EMBASE
7230	FILE ESBIOBASE
10	FILE FROSTI
30	FILE FSTA
551	FILE GENBANK
15	FILE HEALSAFE
370	FILE IFIPAT
9	FILE IMSDRUGNEWS
8	FILE IMSRESEARCH
1738	FILE JICST-EPLUS
50	FILE KOSMET
5161	FILE LIFESCI
14017	FILE MEDLINE
93	FILE NTIS
1	FILE NUTRACEUT
168	FILE OCEAN
6612	FILE PASCAL
5	FILE PHAR
5	FILE PHARMAML
36	FILE PHIN
289	FILE PROMT
13	FILE PROUSDDR
8	FILE RDISCLOSURE
10143	FILE SCISEARCH
4249	FILE TOXCENTER

```
             7252   FILE USPATFULL
              701   FILE USPAT2
                3   FILE VETB
              112   FILE VETU
               12   FILE WATER
              568   FILE WPIDS
                5   FILE WPIFV
              568   FILE WPINDEX
               33   FILE IPA
               12   FILE NAPRALERT
              207   FILE NLDB
L1               QUE SECRET?(S)(LYSOS? OR GRANUL?)
                 ---------
                 D RANK

     FILE 'BIOSIS, MEDLINE, CAPLUS, EMBASE, SCISEARCH, USPATFULL, ESBIOBASE,
     BIOTECHNO, PASCAL, LIFESCI, TOXCENTER, CABA' ENTERED AT 21:57:35 ON 02
     JUN 2006
L2        108725 SEA SECRET?(S)(LYSOS? OR GRANUL?)
L3          9324 SEA L2(S) LOCAL?
L4           887 SEA L3(S)(PROTEAS? OR TRYPTAS? OR CHYMAS? OR CATHEPS? OR
                 CARBOXYPEPTIDAS? OR PROTEINAS? OR HEXOSAMIDA?)
L5           716 SEA L4(S) CELL?
L6           146 SEA L5(S) MAST?
L7            76 DUP REM L6 (70 DUPLICATES REMOVED)
                 D TI L7 1-76
                 D IBIB ABS L7 6 8 11 24 29 30 33 36 37 39 54 58 64 74 76
L8            27 SEA L7 AND FUS?
                 D TI L8 1-28
L9           181 SEA L5 AND MAST?
L10           60 SEA L9 AND FUS?
L11           59 DUP REM L10 (1 DUPLICATE REMOVED)
                 D TI L11 1-59
                 D L11 IBIB ABS 21 47 53 58


     FILE HOME

     FILE STNINDEX

     FILE BIOSIS
     FILE COVERS 1969 TO DATE.
     CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
     FROM JANUARY 1969 TO DATE.

     RECORDS LAST ADDED: 31 May 2006 (20060531/ED)


     FILE MEDLINE
      FILE LAST UPDATED: 2 JUN 2006 (20060602/UP).  FILE COVERS 1950 TO DATE.

      On December 11, 2005, the 2006 MeSH terms were loaded.

      The MEDLINE reload for 2006 is now (26 Feb.) available.  For details
      on the 2006 reload, enter HELP RLOAD at an arrow prompt (=>).
      See also:

         http://www.nlm.nih.gov/mesh/
         http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html
         http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_med_data_changes.html
         http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_2006_MeSH.html

      OLDMEDLINE is covered back to 1950.

      MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the
```